Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1) - Test2 - elhamkhani - TriplyDB

Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1)

Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1)

http://www.wikidata.org/entity/Q30521394

about

Patient-identified disease burden in facioscapulohumeral muscular dystrophy.Patient-Reported Impact of Symptoms in Myotonic Dystrophy Type 2 (PRISM-2).Myotonic Dystrophies: State of the Art of New Therapeutic Developments for the CNS.The UK Myotonic Dystrophy Patient Registry: facilitating and accelerating clinical research Hard ways towards adulthood: the transition phase in young people with myotonic dystrophy.Diagnostic odyssey of patients with myotonic dystrophy Quality-of-life in Charcot-Marie-Tooth disease: the patient's perspective.The relationship between physical symptoms and health-related quality of life in oculopharyngeal muscular dystrophy.Parent-reported multi-national study of the impact of congenital and childhood onset myotonic dystrophy.Multidimensional aspects of pain in myotonic dystrophies.Patient identification of the symptomatic impact of charcot-marie-tooth disease type 1A.Myotonic dystrophy health index: Correlations with clinical tests and patient function The Impact of Pregnancy on Myotonic Dystrophy: A Registry-Based Study The Mef2 transcription network is disrupted in myotonic dystrophy heart tissue, dramatically altering miRNA and mRNA expression.Daytime sleepiness and myotonic dystrophy.Activity rating scales in adult muscle disease: what do they actually measure?Sleep-Wake Cycle and Daytime Sleepiness in the Myotonic Dystrophies Evolving Motivations: Patients' and Caregivers' Perceptions About Seeking Myotonic Dystrophy (DM1) and Huntington's Disease Care.Survey of Canadian Myotonic Dystrophy Patients' Access to Computer Technology.Major involvement of trunk muscles in myotonic dystrophy type 1.Medication adherence in patients with myotonic dystrophy and facioscapulohumeral muscular dystrophy.Quantitative Assessment of Trunk Muscles Involvement in Patients with Myotonic Dystrophy Type 1 Using a Whole Body Muscle Magnetic Resonance Imaging.Myotonic Dystrophy Type 1 Management and Therapeutics.Review of patient-reported outcome measures for use in myotonic dystrophy type 1 patients.Myotonic Dystrophy and Huntington's Disease Care: "We Like to Think We're Making a Difference".Variability of multisystemic features in myotonic dystrophy type 1--lessons from Serbian registry.Pain location and intensity impacts function in persons with myotonic dystrophy type 1 and facioscapulohumeral dystrophy with chronic pain.Myotonic Dystrophy Health Index: initial evaluation of a disease-specific outcome measure.Patient-identified impact of symptoms in spinal and bulbar muscular atrophy.Truths and misinformation: a qualitative exploration of myotonic dystrophy.The impact of congenital and childhood myotonic dystrophy on quality of life: a qualitative study of associated symptoms.French translation and cross-cultural adaptation of The Myotonic Dystrophy Health Index.Orexin/hypocretin levels in the cerebrospinal fluid and characteristics of patients with myotonic dystrophy type 1 with excessive daytime sleepiness.Increased EEG Theta Spectral Power in Sleep in Myotonic Dystrophy Type 1.Outcome Measures for Central Nervous System Evaluation in Myotonic Dystrophy Type 1 May Be Confounded by Deficits in Motor Function or Insight

P2860

Q30583657-6EBAC870-9F10-48AC-ABC6-1813F78AFA8B Q30692540-3CF63894-0B3C-4EF6-A299-BF8E00BE6E9B Q33580885-6AA87A81-5BDB-4AE1-B2F7-92879EC4AD3E Q33627845-50D77405-A1AD-467E-8465-4E364D6AEBBD Q33635770-50F73ECE-F046-49F9-B39B-8F07768B88B7 Q34172180-9E8E0BB7-8907-4FA1-A434-C974B090E9E2 Q34621607-340BC9B4-8E57-4DB5-BE6E-17F17C11105E Q36783791-C2A3C1C5-733A-4A71-91C6-AFE975F680EE Q36844836-6F3CD5D5-8D4D-4F50-9656-05FAD5CDFD39 Q36876599-76DB5520-881B-4E2C-8542-9B51477F2820 Q37119243-264C47F1-619A-496B-950B-108567885FAD Q37165392-89EEAD24-1F76-4081-B1AE-480C34EA6CFB Q37589784-E0C791B3-1345-4169-8726-A53600F1F984 Q37590150-A5BD6B7B-AB00-4689-9098-748371974391 Q38083615-7C89909B-8E4C-4AA7-A6F6-883B10C57508 Q38152335-3B3A2228-D7EC-4C5C-A3B5-CA119D9B1275 Q38575770-B9D9C90E-9C2B-4A11-B22E-E9348DB1D513 Q38629175-FA2CF5EB-AA2A-450A-BEC8-FE7D207E2ADF Q38768565-583B4EE1-1090-40CA-8D3A-2798453CC394 Q38809790-0F1B1185-ECB3-4C2B-A80B-83EE8F7A1071 Q38812196-B52CA2AE-B025-4832-9C37-5A207BABCD88 Q38910890-0DF1DEB7-824A-491F-9345-38234124EB03 Q39003493-C6D7535A-61E0-4C42-AFA6-84FD358369A8 Q39012912-C4460681-812D-44F2-945D-D01F09EEDBCA Q39349990-B23C2659-BAB1-40BB-88D7-B922B3518951 Q40726509-EDFC8588-48BA-4942-863E-E94FEDD2BC1A Q41205792-5A8C7CB6-105F-4C02-9E13-AF031356FA60 Q41345571-E397FDC7-3EF3-47BF-B0E1-D9CC2A8D47CF Q47298620-A68DCE92-2937-4D22-A5FA-2B67FEF3A229 Q47717264-50E20115-C75D-4640-9644-9A67674F5FE3 Q48256312-62B18AF8-0EED-493E-85D9-1C4409A93159 Q48570241-C2B94B57-8948-4445-8EE6-8CF7B9A2AF0B Q49502636-3394EB5A-E259-417C-8160-7FD9032A5F47 Q50210167-A06DC286-F799-4BEC-817B-CFE3CD107472 Q58586761-C4EBFE06-D33B-4AB3-92B8-0A33957BF3EA

P2860

Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1)

http://www.wikidata.org/entity/Q30521394

description

2012 nî lūn-bûn

@nan

2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1)

@ast

Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1)

@en

type

label

Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1)

@ast

Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1)

@en

prefLabel

Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1)

@ast

Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1)

@en

P1433

Q30521394-34D477ED-FDD0-4703-870C-2F9B9A778A26

P1476

Q30521394-E8812DAE-FDD9-49AA-BD39-42279FFCE066

P2093

Q30521394-322A33FF-334E-495D-9A62-CB31BE201586

Q30521394-42D91392-0454-4C25-9EA9-D3055E506462

Q30521394-5098AD1B-A38B-4785-96B8-8DEB4133DB06

Q30521394-6881E6B4-68DC-4B26-99DA-90ACF7E4D684

Q30521394-699D5295-A721-4ED4-8451-28F481ACB8DE

Q30521394-9AAED147-F8F1-4044-9762-23B933A6BE40

Q30521394-C2CB7C43-1567-48D3-AEBE-B35D6F9606A3

Q30521394-DD36A6BC-BCE0-4C44-9184-E4860623A043

Q30521394-EFE6E46E-B5C4-4377-A15F-63F09E5B7756

Q30521394-F2427492-E4C4-4D70-BF7E-3FEAB645FC04

P2860

Q30521394-344AE802-5D25-4D83-8011-C1517C71CCAC

Q30521394-3F89ECEE-D178-4391-8D43-1F425774DF38

Q30521394-686D87DA-AF08-4ADD-B14D-010447A91B04

Q30521394-76E87FE3-4369-4DB3-88C1-6DA43C87C806

Q30521394-770DD6A3-2E0F-4A70-B473-483F3A18DA6B

Q30521394-940B282E-0264-424A-A76C-BAEF54C84895

Q30521394-95CCE4D0-20E5-4081-8189-9264D20A25CD

Q30521394-98EE66B3-4147-4283-B9CE-7CF4A5B3DD89

Q30521394-A30F4BA6-D38C-4901-B00A-C04949F7EDE9

Q30521394-E02FCC4F-680E-4C48-A070-4EDF544F7B7F

P304

Q30521394-6D73722D-23A3-4909-80F3-09C1F4848768

P31

Q30521394-6FBA047F-9541-4C2F-8484-D4375957CC94

P356

Q30521394-69D24B5E-D752-44C3-BE32-578309DF7BA5

P407

Q30521394-17A3502E-6EDF-4011-ADF0-5D28D1332F73

P433

Q30521394-5E46D702-43BC-4605-BE91-FCECBEC4CD6C

P478

Q30521394-82FCEC7D-36B9-46DB-B925-802F1AEE4570

P577

Q30521394-4AF2978E-A204-4AA2-A8DB-23D692E046BD

P698

Q30521394-C08B0A25-FD08-4A4E-83F8-6437BA5AAEA6

P921

Q30521394-179005D7-EF22-4B37-AE79-B0388085F2A4

P932

Q30521394-2DE179CA-531E-4256-A069-0F044E3EC0B8

P356

WNL.0B013E318260CBE6

P1433

P1476

Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1)

@en

P2093

Barbara Vickrey

http://www.w3.org/2001/XMLSchema#string

Chad Heatwole

http://www.w3.org/2001/XMLSchema#string

Charles Thornton

http://www.w3.org/2001/XMLSchema#string

Christine Quinn

http://www.w3.org/2001/XMLSchema#string

David Victorson

http://www.w3.org/2001/XMLSchema#string

Michael P McDermott

http://www.w3.org/2001/XMLSchema#string

Nan Rothrock

http://www.w3.org/2001/XMLSchema#string

Nicholas Johnson

http://www.w3.org/2001/XMLSchema#string

Richard Moxley

http://www.w3.org/2001/XMLSchema#string

Rita Bode

http://www.w3.org/2001/XMLSchema#string

P2860

Prevalence of irritable bowel syndrome: a community survey.

Myotonic dystrophy mutation: an unstable CTG repeat in the 3' untranslated region of the gene

Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance

Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member.

If you build a rare disease registry, will they enroll and will they use it? Methods and data from the National Registry of Myotonic Dystrophy (DM) and Facioscapulohumeral Muscular Dystrophy (FSHD).

An unstable triplet repeat in a gene related to myotonic muscular dystrophy.

High disease impact of myotonic dystrophy type 2 on physical and mental functioning

Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001.

Patient-reported outcomes to support medical product labeling claims: FDA perspective.

Health supervision and anticipatory guidance in adult myotonic dystrophy type 1.

P304

348-357

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/WNL.0B013E318260CBE6

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

79

http://www.w3.org/2001/XMLSchema#string

P577

2012-07-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22786587

http://www.w3.org/2001/XMLSchema#string

P921

P932

3400095

http://www.w3.org/2001/XMLSchema#string